Valentin Fuster, MD, PhD, former Chairman of the American Heart Association's Committee on Vascular Lesions, Assessing and Modifying the Vulnerable Atherosclerotic Plaque explores the most cutting-edge developments in a field grown richer through technological advances.

• 1. Cardiovascular defense challenges at the basic, clinical, and population levelsJason C. Kovacic, Jose M. Castellano, and Valentin Fuster7. Plaque neovascularizationl defense mechanisms, betrayal, or a war in progressPedro R. Moreno, Meeranani Purushothaman, and K-Raman Purushothaman18. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaosLina Badimon and Gemma Vilahur33. Evolving role of molecular imaging for new understanding: targeting myofibroblasts to predict remodelingHans J. de Haas, Susanne W. van den Borne, Hendrikus H. Boersma, Riemer H.J.A. Slart, Valentin Fuster, and Jagat Narula42. Molecular targets in heart failure gene therapy: current controversies and translational perspectivesVictor Kairouz, Larissa Lipskaia, Roger J. Hajjar, and Elie R. Chemaly51. Engineered arterial models to correlate blood flow to tissue biological responseJordi Martorell, Pablo Santomá, José J. Molins, Andrés A. García-Granada, José A. Bea, Elazer R. Edelman, and Mercedes Balcells57. A bird’s-eye view of cell therapy and tissue engineering for cardiac regenerationCarolina Soler-Botija, Juli R. Bagó, and Antoni Bayes-Genis66. Umbilical cord blood for cardiovascular cell therapy: from promise to factSantiago Roura, Josep-Maria Pujal, and Antoni Bayes-Genis71. Heart repair: from natural mechanisms of cardiomyocyte production to the design of new cardiac therapiesSilvia Martin-Puig, Valentín Fuster, and Miguel Torres82. Energy metabolism plasticity enables stemness programsClifford D.L. Folmes, Timothy J. Nelson, Petras P. Dzeja, and Andre Terzic90. The future: therapy of myocardial protectionDavid Sanz-Rosa, Jaime Garcia-Prieto, and Borja Ibanez99. The links between complex coronary disease, cerebrobascular disease, and degenerative brain diseaseJason C. Kovacic, Jose M. Castellano, and Valentin Fuster106. Optimal lipid targets for the new era of cardiovascular preventionVimal Ramjee, danny J. Eapen, and Laurence S. Sperling115. Controversies in blood pressure goal guidelines and masked hypertensionRobert A. Phillips123. Evolving diagnostic and prognostic imaging of the various cardiomyopathiesJavier Sanz131. The evolving landscape of quality measurement for heart failureAshley A. Fitzgerald, Larry A. Allen, and Frederick A. Masoudi140. Atrial Fibrillation, Stock, and quality of lifeJason S. Chinitz, Jose M. Castellano, Jason C. Kovacic, and Valentin Fuster151. Transcatheter aortic valve implantation and cerebrovascular events: the current state of the artBrian G. Hynes and Josep Rodés-Cabau164. Are we ignoring the dilated thoracic aortia?Jose M. Castellano, Jason C. Kovacic, Javier Sanz, and Valentin Fuster175. Corrigendum

Valentin Fuster, MD, PhD, former Chairman of the American Heart Association's Committee on Vascular Lesions, Assessing and Modifying the Vulnerable Atherosclerotic Plaque explores the most cutting-edge developments in a field grown richer through technological advances.

• 1. Cardiovascular defense challenges at the basic, clinical, and population levelsJason C. Kovacic, Jose M. Castellano, and Valentin Fuster7. Plaque neovascularizationl defense mechanisms, betrayal, or a war in progressPedro R. Moreno, Meeranani Purushothaman, and K-Raman Purushothaman18. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaosLina Badimon and Gemma Vilahur33. Evolving role of molecular imaging for new understanding: targeting myofibroblasts to predict remodelingHans J. de Haas, Susanne W. van den Borne, Hendrikus H. Boersma, Riemer H.J.A. Slart, Valentin Fuster, and Jagat Narula42. Molecular targets in heart failure gene therapy: current controversies and translational perspectivesVictor Kairouz, Larissa Lipskaia, Roger J. Hajjar, and Elie R. Chemaly51. Engineered arterial models to correlate blood flow to tissue biological responseJordi Martorell, Pablo Santomá, José J. Molins, Andrés A. García-Granada, José A. Bea, Elazer R. Edelman, and Mercedes Balcells57. A bird’s-eye view of cell therapy and tissue engineering for cardiac regenerationCarolina Soler-Botija, Juli R. Bagó, and Antoni Bayes-Genis66. Umbilical cord blood for cardiovascular cell therapy: from promise to factSantiago Roura, Josep-Maria Pujal, and Antoni Bayes-Genis71. Heart repair: from natural mechanisms of cardiomyocyte production to the design of new cardiac therapiesSilvia Martin-Puig, Valentín Fuster, and Miguel Torres82. Energy metabolism plasticity enables stemness programsClifford D.L. Folmes, Timothy J. Nelson, Petras P. Dzeja, and Andre Terzic90. The future: therapy of myocardial protectionDavid Sanz-Rosa, Jaime Garcia-Prieto, and Borja Ibanez99. The links between complex coronary disease, cerebrobascular disease, and degenerative brain diseaseJason C. Kovacic, Jose M. Castellano, and Valentin Fuster106. Optimal lipid targets for the new era of cardiovascular preventionVimal Ramjee, danny J. Eapen, and Laurence S. Sperling115. Controversies in blood pressure goal guidelines and masked hypertensionRobert A. Phillips123. Evolving diagnostic and prognostic imaging of the various cardiomyopathiesJavier Sanz131. The evolving landscape of quality measurement for heart failureAshley A. Fitzgerald, Larry A. Allen, and Frederick A. Masoudi140. Atrial Fibrillation, Stock, and quality of lifeJason S. Chinitz, Jose M. Castellano, Jason C. Kovacic, and Valentin Fuster151. Transcatheter aortic valve implantation and cerebrovascular events: the current state of the artBrian G. Hynes and Josep Rodés-Cabau164. Are we ignoring the dilated thoracic aortia?Jose M. Castellano, Jason C. Kovacic, Javier Sanz, and Valentin Fuster175. Corrigendum

Valentin Fuster, MD, PhD, former Chairman of the American Heart Association's Committee on Vascular Lesions, Assessing and Modifying the Vulnerable Atherosclerotic Plaque explores the most cutting-edge developments in a field grown richer through technological advances.

• 1. Cardiovascular defense challenges at the basic, clinical, and population levelsJason C. Kovacic, Jose M. Castellano, and Valentin Fuster7. Plaque neovascularizationl defense mechanisms, betrayal, or a war in progressPedro R. Moreno, Meeranani Purushothaman, and K-Raman Purushothaman18. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaosLina Badimon and Gemma Vilahur33. Evolving role of molecular imaging for new understanding: targeting myofibroblasts to predict remodelingHans J. de Haas, Susanne W. van den Borne, Hendrikus H. Boersma, Riemer H.J.A. Slart, Valentin Fuster, and Jagat Narula42. Molecular targets in heart failure gene therapy: current controversies and translational perspectivesVictor Kairouz, Larissa Lipskaia, Roger J. Hajjar, and Elie R. Chemaly51. Engineered arterial models to correlate blood flow to tissue biological responseJordi Martorell, Pablo Santomá, José J. Molins, Andrés A. García-Granada, José A. Bea, Elazer R. Edelman, and Mercedes Balcells57. A bird’s-eye view of cell therapy and tissue engineering for cardiac regenerationCarolina Soler-Botija, Juli R. Bagó, and Antoni Bayes-Genis66. Umbilical cord blood for cardiovascular cell therapy: from promise to factSantiago Roura, Josep-Maria Pujal, and Antoni Bayes-Genis71. Heart repair: from natural mechanisms of cardiomyocyte production to the design of new cardiac therapiesSilvia Martin-Puig, Valentín Fuster, and Miguel Torres82. Energy metabolism plasticity enables stemness programsClifford D.L. Folmes, Timothy J. Nelson, Petras P. Dzeja, and Andre Terzic90. The future: therapy of myocardial protectionDavid Sanz-Rosa, Jaime Garcia-Prieto, and Borja Ibanez99. The links between complex coronary disease, cerebrobascular disease, and degenerative brain diseaseJason C. Kovacic, Jose M. Castellano, and Valentin Fuster106. Optimal lipid targets for the new era of cardiovascular preventionVimal Ramjee, danny J. Eapen, and Laurence S. Sperling115. Controversies in blood pressure goal guidelines and masked hypertensionRobert A. Phillips123. Evolving diagnostic and prognostic imaging of the various cardiomyopathiesJavier Sanz131. The evolving landscape of quality measurement for heart failureAshley A. Fitzgerald, Larry A. Allen, and Frederick A. Masoudi140. Atrial Fibrillation, Stock, and quality of lifeJason S. Chinitz, Jose M. Castellano, Jason C. Kovacic, and Valentin Fuster151. Transcatheter aortic valve implantation and cerebrovascular events: the current state of the artBrian G. Hynes and Josep Rodés-Cabau164. Are we ignoring the dilated thoracic aortia?Jose M. Castellano, Jason C. Kovacic, Javier Sanz, and Valentin Fuster175. Corrigendum